Cannabis Research Explores What’s Better: The Illicit Market or Legal Market
by Chane Leigh
*September 12, 2019 Update*
The DEA has officially proposed a significant increase in cannabis grown for research.
In one of the greatest songs ever written about cannabis prohibition, “Who’s the Pusher Now,” Ellen Bukstel states, “our taxes pay the FDA, so the DEA can put us away.” Despite the federal prohibition of cannabis, the DEA is set to release a statement on Sept. 12th, that calls for “3,200,000 grams of marijuana to be legally grown in the U.S. next year” according to a report in Forbes.
To put that into perspective, 3.2 million grams is equal to 114,285 ounces or 7,142 pounds of cannabis. This proposed quota is more than 30% higher than the 2,450,000 grams or 5,468 pounds that will be grown this year by the U.S. Government. So why is the DEA requesting this much cannabis to be grown while they stand behind federal prohibition and continue to incarcerate people for the same plant?
Simple. Cannabis is going mainstream, and people want answers. By answers we’re talking the kind that may finally put an end to the outdated stigma and downright lies that continue to be spread about this miraculous plant.
According to the official press release from the DEA regarding this proposed quota, “This will meet the need created by the increase in the amount of approved research involving marijuana.” Based on their reports, it seems that the number of researchers who are registered with the DEA to perform studies regarding cannabis, its derivatives and extracts has significantly increased in recent years. They report that in January of 2017, there were only 384 applicable researchers registered. This number increased to 542 in just two years.
For several decades now, the only government-approved grower of cannabis has been the University of Mississippi. This, however, will hopefully soon change because most researchers are discovering that cannabis grown by the University is far from the cannabis found in legal and illicit markets today.
The average THC content in dried cannabis flower in regulated legal markets ranges anywhere from 10-30%. The cannabis from the only government-approved source, however, tests closer to 7% on average. This means it is far from being what is utilized by thousands of patients nationwide.
This in itself negates any research being performed as the results are based on subpar quality and potency, not on what is being utilized by patients and recreational consumers. A prime example of this can be seen in the studies concluded by Dr. Sue Sisley and her partner, the Multidisciplinary Association for Psychedelic Studies last year.
Dr. Sisley has stated before, and it remains true today, the DEA is conducting a “continuous attack on scientific study.” The research material she received for her study surrounding PTSD has been described as “homogenous green dust,” and there is little known information regarding the cannabinoids and terpenes that it contains. This isn’t science. It’s a shame.
As long as the federal prohibition remains, the only approved source for researchers working with cannabis are the ones approved by the DEA. When researchers can obtain quality cannabis like what is being utilized by patients, it is likely we will begin to see substantial scientific evidence of the benefits cannabis offers.
Luckily there may be light at the end of the tunnel. Just last month, the National Institute of Health and the Federal Drug Administration penned a letter to Senator Brian Schatz of Hawaii regarding this issue. The message made mention of how prohibition limits not only the quality but also the diversity of cannabis being utilized for research. They also showed their support for researchers to be able to obtain cannabis from state-licensed dispensaries rather than the University of Mississippi.
In addition to their proposed quota of cannabis to be grown, the Federal Register notice states that the DEA is requesting the following also be produced next year for research purposes.
They are also requesting for a drastic reduction in the amount of hydrocodone, hydromorphone, oxycodone, oxymorphone, and fentanyl being produced in the U.S. This is excellent news considering the detrimental damage that has been suffered by communities globally as a result of the opioid epidemic. It is great to see that the DEA is starting to allow for more research, however, as you can see, it is a catch-22 if the only cannabis able to be utilized is far from the quality of cannabis being consumed by patients.
Need help .
Looking to find your medical cannabis in a state that hasn’t yet legalized it? It may be tempting to drive across neighboring state lines with more cannabis-friendly laws. However, the number of states that will authorize qualified patients from out-of-state medical marijuana programs is still relatively small. Which States Accept Out-of-State MMJ Cards? States That…
Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. But there may be some good news for those coping with this mental health issue. According to recent research, cannabis could offer unique benefits as part of an approach to managing bipolar…
The war on drugs facilitated by the federal government has been an utter failure. Despite cannabis remaining a Schedule I classification according to the federal Controlled Substances Act (CSA), meaning that it has no medicinal value, over 30 states in the United States have legalized it for its medicinal use. While this classification will remain…
Three different types of cannabidiol (CBD) oils produced by Charlotte’s Web have been banned by British regulators. The British Food Standards Agency (FSA) has also disqualified approximately 100 CBD products for undisclosed reasons. In 2018, legislation was passed by the British Parliament that effectively legalized cannabinoids like CBD and CBDA. Despite the law’s passing, CBD…
As cannabis enthusiasts, we’re all too familiar with the stigma surrounding its use and the hoops that have to be jumped through to get it into medical research trials. But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. In light of this, one…
We sat down with the team at TerraLeaf, a medical cannabis dispensary servicing West Virginia, to ask them the Veriheal 5—five questions…
We all know that cannabis and prednisone can affect our bodies differently when used separately. But if you’re dealing with a pretty…
A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD)—the primary non-intoxicating constituent of cannabis…